Kazia Therapeutics Limited – Filings and Transcripts

NASDAQ: KZIA
Share price (3/27/26): $7.16
Market cap (3/27/26): $81.8 million

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 06/30/25 FY 2025

Late filing notification for annual report of foreign issuer

ended 06/30/24 FY 2024

Late filing notification for annual report of foreign issuer

ended 06/30/23 FY 2023

Prospectuses and Registrations Filter

Prospectus supplement

Prospectus supplement

Prospectus supplement

Prospectus supplement

Shelf registration

Ownership Filter

Coffey Steven R. S.

Friend John E. II

Bonacorda Jeffrey

News Filter

Principal Activities

Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer

Material disclosure

Highlights New Clinical and Translational Findings Demonstrating Paxalisib’s Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations Including TNBC and HER2+

Material disclosure

Proxies

No filings in this category.

Other Filter

Notice of effectiveness

Notice of effectiveness

Notice of effectiveness

Notice of effectiveness

Notice of effectiveness